FDA Brief

Warning letters Biologics

FDA warning letter to

Toxikon Corporation/Labcorp Bedford LLC

MediumIssued Feb 10, 2022Posted Feb 22, 2022Center for Biologics Evaluation and Research

FDA warned Toxikon/Labcorp Bedford over GLP violations in a biologics nonclinical study, including incorrect kidney-function calculations and failed QA review.

What happened

FDA inspected the facility from August 13 to September 14, 2021 and reviewed a nonclinical GLP study. It found multiple calculation errors in plasma volume, urine output, GFR and RBF, plus QA review failures and other documentation and sample-identification problems.

What FDA found

  1. The study director did not ensure experimental data were accurately recorded and verified, because plasma volume was calculated with the wrong formula and caused many GFR and RBF values to be wrong.

    21 CFR § 58.33(b)
  2. Urine output at the one-hour timepoint was calculated incorrectly, and many RPF, RBF and GFR values were not corrected before the final report.

    21 CFR § 58.33(b)
  3. The quality assurance unit did not review the final study report adequately and missed calculation errors and uncorrected urine-output errors.

    21 CFR § 58.35(b)(6)
  4. The study director failed to ensure proper identification of multiple blood and urine samples and failed to document concentrations and dilutions adequately.

  5. The study director did not document unforeseen circumstances or ensure corrective action was taken and documented, including missed animal dosings.

  6. The final study report did not describe certain issues, mislabeled vials, all protocol calculations, and protocol deviations.

What FDA wants

FDA asks the company to investigate causes, take prompt corrective actions, and respond in writing within 15 working days with documentation and Excel files containing underlying calculations and formulas for pages 34-43.

Who should pay attention

  • sponsors relying on Toxikon/Labcorp Bedford for GLP studies
  • contract research labs conducting nonclinical studies
  • quality assurance units and study directors for biologics developers

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Lovelace Biomedical Research Institute

    Lovelace Biomedical's quality unit failed to ensure final drug study reports matched raw data, FDA says.

    Medium
  2. HealthPartners Neuroscience Center Research and Innovation

    FDA warned HealthPartners Neuroscience Center that its animal studies of an investigational drug violated good laboratory practice rules.

    Medium
  3. Vedic Lifesciences Pvt. Ltd.

    FDA warns Vedic Lifesciences over false final reports for three nonclinical drug studies.

    Medium
  4. Palamur Biosciences Private Limited

    FDA warns Palamur Biosciences over GLP violations in medical device safety testing and inadequate corrective actions.

    High risk